|
"AT-less" Type I Polyketide Synthases
|
5R01CA106150-04
|
$281,102
|
SHEN, BEN
|
UNIVERSITY OF WISCONSIN MADISON
|
|
(CRCL) vaccine for Chronic Myelogenous Leukemia
|
5R01CA104926-04
|
$264,158
|
KATSANIS, EMMANUEL
|
UNIVERSITY OF ARIZONA
|
|
15-Deoxy-D12, 14-PGE, J2 as a ligand of RXRalpha
|
5R01CA109345-04
|
$455,425
|
ZHANG, XIAO-KUN
|
BURNHAM INSTITUTE FOR MEDICAL RESEARCH
|
|
2006 Molecular Therapeutics of Cancer Gordon Research Conference
|
5R13CA124132-02
|
$4,855
|
EASTMAN, ALAN
|
GORDON RESEARCH CONFERENCES
|
|
4-Peroxycyclophosphamides for Brain Tumor Therapy
|
5R01CA100074-04
|
$217,702
|
STRUCK, ROBERT
|
CANCERMEDICA, LLC
|
|
A Biomarker Study of COX-2 Inhibitors in IPMN
|
5R03CA112629-02
|
$73,553
|
Schmidt, Christian
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
A Concerted Chemical, Biophysical and Molecular Biological Attack of Intracellul*
|
2P01CA095471-06
|
$3,786,785
|
MCKNIGHT, STEVEN
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
|
A Derivative of Oleanolic Acid: Anti-HCC Activity
|
5R21CA116846-02
|
$142,519
|
TIAN, JIDE
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
A Drosophila Model for MEN2 and Sporadic MTCs
|
5R01CA084309-07
|
$212,392
|
Cagan, Ross
|
WASHINGTON UNIVERSITY
|
|
A Drosophila model for the electrophile counter-attack chemoprevention strategy
|
5R03CA123591-02
|
$74,767
|
BOHMANN, DIRK
|
UNIVERSITY OF ROCHESTER
|
|
A new method for delivery of selinium for prevention of melanoma
|
5R03CA125854-02
|
$72,582
|
Cassidy, Pamela
|
UNIVERSITY OF UTAH
|
|
A novel biotherapeutic treatment for prostate cancer
|
1R43CA130228-01
|
$145,306
|
CHOI, ANTHONY
|
BEXION PHARMACEUTICALS, INC.
|
|
A Novel Inhibitor of Stat3 for Prostate Cancer Therapy
|
5R01CA104035-03
|
$280,899
|
JING, NAIJIE
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Novel Oncolytic HSP Vaccine for Systemic Tumor Therapy
|
5R01CA100841-02
|
$206,823
|
HUANG, XUE
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Novel Ring Finger Protein in Cancer Drug Resistance
|
5R01CA106625-05
|
$221,768
|
RAO, U
|
TEXAS TECH UNIVERSITY HEALTH SCIS CENTER
|
|
A Novel Strategy for Defining and Targeting Cancer Addiction to Anti-Apoptotic BC
|
1R01CA129974-01A1
|
$324,900
|
LETAI, ANTHONY
|
DANA-FARBER CANCER INSTITUTE
|
|
A novel sulindac derivative for colon cancer chemoprevention
|
1R03CA128021-01
|
$108,011
|
PIAZZA, GARY
|
SOUTHERN RESEARCH INSTITUTE
|
|
A NOVEL TARGETED THERAPEUTIC USING VIRAL CAPSID PROTEIN
|
1R21CA116014-01A2
|
$159,000
|
MEDINA-KAUWE, LALI
|
CEDARS-SINAI MEDICAL CENTER
|
|
A Novel Vitamin D Target in Human Prostate Cancer
|
5R21CA113380-02
|
$113,523
|
BEER, TOMASZ
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
A Nucleosomal Biosensor for Identification and Isolation of Nuclear Hormone Recep
|
1R21CA125514-01
|
$167,063
|
STEINMAN, RICHARD
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
A Phase 2 Trial of Dasatinib in Patients with NSCLC and Acquired Resistance to Er
|
1R21CA130343-01
|
$226,200
|
MILLER, VINCENT
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
A POLYMERIC DRUG DELIVERY SYSTEM FOR CANCER THERAPY
|
5R01CA051578-15
|
$236,153
|
KOPECEK, JINDRICH
|
UNIVERSITY OF UTAH
|
|
A Shielded Conditionally Replicative Adenoviral Vector
|
1R43CA123768-01A1
|
$100,000
|
KOVESDI, IMRE
|
VECTORLOGICS, INC.
|
|
A software tool for optimizing the solubility of therapeutic proteins.
|
1R43CA128213-01
|
$121,820
|
WHITTEN, STEVEN
|
REDSTORMSCIENTIFIC, INC.
|
|
A Tumor Specific Therapy Approach for Small Cell Lung Cancer
|
5R21CA104297-02
|
$122,501
|
ZOU, YIYU
|
YESHIVA UNIVERSITY
|
|
A Two Hybrid System Based Yeasy Screen for Agents that Affect DNA Damage Checkpoi
|
1R43CA130224-01
|
$135,446
|
KUMAR, NALIN
|
UHV TECHNOLOGIES, INC.
|
|
A Yeast Model for Determining Tubulin-drug Interactions
|
5R01CA105305-04
|
$251,912
|
HIMES, RICHARD
|
UNIVERSITY OF KANSAS LAWRENCE
|
|
A-007: Immune Modulation of HPV - Associated Neoplasia
|
5R44CA089772-04
|
$776,869
|
NGUYEN, BINH
|
TIGRIS PHARMACEUTICALS, INC.
|
|
ABCB5 P-Glycoprotein in Cancer Multidrug Resistance
|
5R01CA113796-02
|
$291,276
|
Frank, Markus
|
CHILDREN'S HOSPITAL BOSTON
|
|
Aberrant Crypt Foci as a Biomarker for Chemoprevention
|
5R01CA113681-02
|
$462,908
|
SINICROPE, FRANK
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-32S1
|
$215,193
|
THOMPSON, CRAIG
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
5P30CA016520-32
|
$7,282,327
|
Thompson, Craig
|
UNIVERSITY OF PENNSYLVANIA
|
|
Acquired Resistance to VEGF blockade in Wilms tumor
|
5R01CA100451-05
|
$310,442
|
KANDEL, JESSICA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
ACSB Central Operations and Data Coodinating Center
|
3U01CA096230-05S1
|
$459,957
|
MCGRATH, MICHAEL
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
Acylation as an Approach to Enhance the Cancer Preventive Effect of EGCG
|
5R03CA121390-02
|
$75,010
|
Sang, Shengmin
|
RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK
|
|
Acyltransferase Inhibitors as Anti Ras Agents
|
5R01CA075248-12
|
$235,339
|
SMITH, CHARLES
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Adaptive Immunity from High Affinity Anti-HER2/neu Monoclonal Antibodies
|
5R01CA121033-02
|
$342,880
|
WEINER, LOUIS
|
FOX CHASE CANCER CENTER
|
|
Adenosine Analogs: Therapeutics for Hematologic Cancers
|
3R01CA085915-07S1
|
$51,498
|
ROSEN, STEVEN
|
NORTHWESTERN UNIVERSITY
|
|
Adenosine Analogs: Therapeutics for Hematologic Cancers
|
5R01CA085915-07
|
$312,066
|
ROSEN, STEVEN
|
NORTHWESTERN UNIVERSITY
|
|
Adult Leukemia Research Center
|
2P01CA018029-32
|
$5,086,500
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Advanced Anatomic and Functional Response Assessment in Lung Cancer
|
1R01CA125143-01A1
|
$354,322
|
SCHWARTZ, LAWRENCE
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Aerosol Therapy for Lung Cancer
|
5R44CA096409-03
|
$371,115
|
Hansen, Brian
|
AEROPHASE, INC.
|
|
AIDS Malignancy Clinical Trials Corsortium
|
5U01CA121947-02
|
$5,296,416
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Akt1 and erbB2 - New Molecular Targets for Hormone Resistance in Breast Cancer
|
5R03CA117467-02
|
$75,350
|
STOICA, ADRIANA
|
GEORGETOWN UNIVERSITY
|
|
AKT2 Oncogene and Human Oncogenesis
|
5R01CA077935-10
|
$228,571
|
CHENG, JIN
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Aldose Reductase-Like-1, a Novel Hepatocellular Carcinoma Drug Resistant Protein
|
1R21CA122327-01A1
|
$144,500
|
Cao, Deliang
|
SOUTHERN ILLINOIS UNIVERSITY SCH OF MED
|
|
Alkylating Vitamin D Derivative
|
1R41CA126317-01A1
|
$258,398
|
CASTOR, TREVOR
|
APHIOS CORPORATION
|
|
Alkyltransferase Inhibitors for Cancer Chemotherapy
|
5R01CA071976-12
|
$250,931
|
PEGG, ANTHONY
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
Alpha Folate Receptor Mediated GARFTase Inhibitors as Selective Antitumor Agents
|
5R01CA125153-02
|
$253,704
|
GANGJEE, ALEEM
|
DUQUESNE UNIVERSITY
|
|
Alpha-Particle Immunotherapy of Cancer
|
5R01CA055349-15
|
$389,561
|
SCHEINBERG, DAVID
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|